



--: Dashed lines indicate options where the proband/substitute decision maker must indicate a preference for the analysis of secondary findings.

\* Unless preference was indicated prior to loss of competence

† The [ACMG SF v3.2](#) list is defined by: ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG) ([PMID 37347242](#)).